Merck KGaA licenses Idera's TLR9 agonists

IDRA granted Merck KGaA (FSE:MRK) an exclusive, worldwide license to toll-like receptor 9 (TLR9) agonists to treat cancer, excluding use as vaccines. IDRA's lead TLR9 agonists are IMO-2055, which is i...